Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Upgrade
/Free Sign Up
 0
Close

Pfizer Inc (PFE)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
25.720 -0.070    -0.27%
06/09 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  US7170811035 
WKN:  852009
  • Volume: 41,635
  • Bid/Ask: 25.720 / 25.730
  • Day's Range: 25.600 - 25.980
Pfizer 25.720 -0.070 -0.27%

PFE Income Statement

 
Featured here, the Income Statement (earnings report) for Pfizer Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
Advanced Income Statement
Collapse All
Period Ending: 2024
30/06
 2024
31/03
 2023
31/12
 2023
01/10
Total Revenue 13283 14878 14249 13232
Revenue 13283 14878 14249 13232
Other Revenue, Total - - - -
Cost of Revenue, Total 2768 3036 7267 8905
Gross Profit 10515 11842 6982 4327
Total Operating Expenses 10308 10172 15522 15878
Selling/General/Admin. Expenses, Total 3557 3348 4114 3112
Research & Development 2676 2480 2874 2682
Depreciation / Amortization 420 424 399 -
Interest Expense (Income) - Net Operating -778 -790 -688 -695
Unusual Expense (Income) - - - -
Other Operating Expenses, Total 1665 1674 1556 1874
Operating Income 2975 4706 -1273 -2646
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets -342 175 2299 -171
Other, Net 3420 1110 557 877
Net Income Before Taxes -103 3421 -4129 -3352
Provision for Income Taxes -134 293 -795 -964
Net Income After Taxes 31 3128 -3334 -2388
Minority Interest 275 276 274 270
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 24 3120 -3343 -2394
Total Extraordinary Items 17 -5 -26 12
Net Income 41 3115 -3369 -2382
Total Adjustments to Net Income -17 5 26 -12
Income Available to Common Excluding Extraordinary Items 24 3120 -3343 -2394
Dilution Adjustment -15.96 -18.35 4.11 -10.68
Diluted Net Income 56.96 3133.35 -3373.11 -2371.32
Diluted Weighted Average Shares 5696 5697 5647 5646
Diluted EPS Excluding Extraordinary Items 0.004 0.55 -0.597 -0.424
DPS - Common Stock Primary Issue 0.42 0.42 0.41 0.41
Diluted Normalized EPS 0.274 0.445 -0.079 -0.269
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

PFE Comments

Write your thoughts about Pfizer Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email